<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663997</url>
  </required_header>
  <id_info>
    <org_study_id>PR21</org_study_id>
    <nct_id>NCT04663997</nct_id>
  </id_info>
  <brief_title>177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer</brief_title>
  <official_title>A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endocyte</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation&#xD;
      directly to prostate cancer sites in the body. The purpose of this study is to find out&#xD;
      whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard&#xD;
      chemotherapy treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard or usual treatment for this disease is a chemotherapy drug called docetaxel,&#xD;
      given by intravenous every 3 weeks, for up to 12 treatments.&#xD;
&#xD;
      177Lu-PSMA-617 is a new type of therapy for prostate cancer. Laboratory tests show that it&#xD;
      may help slow the growth of prostate cancer. 177Lu-PSMA-617 has been shown to shrink tumours&#xD;
      in animals and has been studied in limited numbers of men with prostate cancer and seems&#xD;
      promising but it is not clear if it can offer better control of prostate cancer compared to&#xD;
      docetaxel chemotherapy .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate at 6 months defined by PSA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate at 6 months defined by PCWG 3</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate at 6 months defined by RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second rPFS in patients who meet the criteria for rPFS and cross over to the alternate therapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to commencement of third line therapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients with decreased PSA from baseline and the magnitude of change</measure>
    <time_frame>3 years</time_frame>
    <description>e.g. ≥ 30%, ≥ 50%, ≥ 90% decline from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) &gt; 24 weeks (RECIST v1.1).</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration including partial response, complete response or stable disease &gt; 24 (RECIST v1.1)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE) profile (CTCAE v5.0)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>177 Lu-PSMA-617</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-PSMA-617</intervention_name>
    <description>IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles</description>
    <arm_group_label>177 Lu-PSMA-617</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2 IV every 3 weeks maximum 12 cycles</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological evidence of prostate cancer with no evidence of small cell component&#xD;
&#xD;
          -  Patients must have castration resistance and metastatic disease with evidence of&#xD;
             biochemical or imaging progression in the setting of surgical/medical castration&#xD;
&#xD;
          -  Progression on treatment with abiraterone and/or enzalutamide, or similar&#xD;
             next-generation androgen receptor (AR) targeted therapy&#xD;
&#xD;
          -  Evidence of PSMA positive metastatic disease, as assessed on PSMA-PET imaging studies&#xD;
             obtained as part of other clinical trial protocols are mandated, provided they are&#xD;
             obtained within a timeframe that meets the requirements of this study. The&#xD;
             radiopharmaceuticals must be based on a lysine-urea-glutamate backbone, with a 18F or&#xD;
             68Ga radionuclide label.&#xD;
&#xD;
          -  Prior orchiectomy, or if on LHRH agonist/antagonist then testosterone &lt; 1.7 nmol/L&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Recover from all previous cancer treatment toxicities to grade ≤ 2 (as per CTCAE v5.0)&#xD;
&#xD;
          -  Male subject ≥ 18 years of age&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with chemotherapy for castration-resistant disease or prior docetaxel&#xD;
             in the castration sensitive (hormone-sensitive) setting ≤ 1 year prior to enrollment.&#xD;
&#xD;
          -  Prior treatment with 177Lu-PSMA (including other radiolabeled therapeutic&#xD;
             PSMA-ligands) or radio-immunotherapy&#xD;
&#xD;
          -  Radiotherapy to target lesions (measurable disease) ≤ 12 weeks prior to enrolment&#xD;
&#xD;
          -  Presence of majority (&gt; 50% of lesions) or large (&gt; 5 cm) soft tissue lesions that are&#xD;
             negative on PSMA-Ligand PET/CT or PSMA-Ligand PET/MR&#xD;
&#xD;
          -  Known parenchymal brain metastases&#xD;
&#xD;
          -  Active epidural disease (treated epidural disease is permitted)&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial.&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Major surgery within 4 weeks of starting study treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Chi</last_name>
    <role>Study Chair</role>
    <affiliation>BCCA - Vancouver Cancer Centre, BC Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois Benard</last_name>
    <role>Study Chair</role>
    <affiliation>BCCA - Vancouver Cancer Centre, BC Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Saad</last_name>
    <role>Study Chair</role>
    <affiliation>CHUM-Centre Hospitalier de l'Universite de Montreal, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Parulekar</last_name>
    <phone>613-533-6430</phone>
    <email>wparulekar@ctg.queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Chi</last_name>
      <phone>604 877-6000</phone>
      <phone_ext>2746</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiano Ferrario</last_name>
      <phone>514 398-8307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Pouliot</last_name>
      <phone>418 525-4444</phone>
      <phone_ext>15598</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRPC</keyword>
  <keyword>docetaxel</keyword>
  <keyword>177Lu-PSMA-617</keyword>
  <keyword>radioligand therapy</keyword>
  <keyword>metastatic prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>177Lu-PSMA-617</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Subject to CCTG Policy</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

